An official website of the United States government
Home
Name
ICT-107
Alternate Names
None
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Patient derived dendritic cell immunotherapy
NSC Number
None
Primary Site
Brain
Histology
Glioblastoma
Remarks
ICT-107 is an autologous (patient-derived) dendritic cell (DC) immunotherapy that targets six different antigens (peptides that are tumor markers: AIM-2, MAGE-1, TRP-2, gp100, HER-2, IL-13Ra2) associated with glioblastoma, a form of brain cancer. At least four of these tumor-associated antigens are highly expressed on cancer stem cells (CSCs). ICT-107 is designed for use following surgical tumor resection of newly diagnosed glioblastoma in combination with standard treatment of radiation and chemotherapy. ICT-107 is a cancer immunotherapy
Coding
This drug should be coded
